Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

Oral safiglipron significantly reduces HbA1c by up to 1.45% in early type 2 diabetes over 32 weeks, demonstrating strong glycemic control.

• Why it matters: Effective, convenient treatments are needed for type 2 diabetes management without fasting or dietary restrictions. This study addresses the gap by evaluating an oral GLP-1 receptor agonist.
• What they did: A phase 3 trial with 284 adults tested three doses of safiglipron versus placebo, measuring HbA1c change, fasting glucose, weight, and secondary metabolic outcomes over 52 weeks.
• The result: Safiglipron improved glycemic measures, modestly reduced weight, and was generally well tolerated, supporting its potential as an effective oral therapy for early type 2 diabetes.